Nuvectra Corporation announced the appointment of Paul Hanchin in the newly created role of President, effective as of April 5, 2016. This new position will be responsible for global customer-facing activities for Nuvectra's Spinal Cord Stimulation (SCS) business. Mr. Hanchin will also be responsible for strategic planning and execution of the company's future Sacral Nerve Stimulation (SNS) and Deep Brain Stimulation (DBS) businesses.

Scott Drees will remain as the company's Chief Executive Officer. Mr. Hanchin comes to Nuvectra with thirty years of experience in the medical device arena, including executive leadership positions at small and large, high-growth companies. Prior to Nuvectra, Mr. Hanchin was Executive Vice President at Flowonix Medical Inc., where he had primary responsibilities for global sales and marketing functions.

Tom Hickman will report to Mr. Hanchin and serve as Executive Vice President, Worldwide Marketing & Strategic Development, with expanded responsibilities for future neurostimulation business units. Mr. Hickman and Mr. Hanchin will work together to execute the launch of Algovita in the United States and expand the company's O.U.S. presence. The company also announced the promotion of Norbert Kaula, Ph.D. to the position of Executive Vice President, R&D. Dr. Kaula will have responsibility for all engineering and product design related functions, including next-generation neurostimulation technologies.

Dr. Kaula has over thirty years of neuroscience experience.